Ads

You May Also Like

Albireo Reports Second Quarter 2018 Financial Results

A4250 Phase 3 trial in PFIC underway A4250 granted rare pediatric disease designation, eligible ...

Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), ...